Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00415454 · ClinicalTrials.gov registry record · Phase 1
Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma
A Phase 1 study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00415454 is a Phase 1 study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 8 participants.
The verdict
NCT00415454, a Phase 1 study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary purpose of this phase I study is to determine the safety of combining replication-competent adenovirus-mediated suicide gene therapy with chemoradiotherapy in patients with non-metastatic pancreatic cancer.
Interventions
- GENETIC Ad5-yCD/mutTKSR39rep-ADP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2006-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00415454
The ClinicalTrials.gov registry entry for NCT00415454 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ad5-yCD/mutTKSR39rep-ADP is the first listed.
NCT00415454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00415454 about?
NCT00415454 is a clinical study titled "Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma". The primary purpose of this phase I study is to determine the safety of combining replication-competent adenovirus-mediated suicide gene therapy with chemoradiotherapy in patients with non-metastatic pancreatic cancer.
What is the current status of trial NCT00415454?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2006-11.
What interventions are being tested in trial NCT00415454?
The interventions under investigation include: Ad5-yCD/mutTKSR39rep-ADP (GENETIC).
Who is sponsoring clinical trial NCT00415454?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.